PMID- 31605163
OWN - NLM
STAT- MEDLINE
DCOM- 20201021
LR  - 20201021
IS  - 1439-099X (Electronic)
IS  - 0179-7158 (Linking)
VI  - 196
IP  - 4
DP  - 2020 Apr
TI  - Role of stereotactic body radiation therapy in the treatment of liver metastases: 
      clinical results and prognostic factors.
PG  - 325-333
LID - 10.1007/s00066-019-01524-8 [doi]
AB  - PURPOSE: To evaluate feasibility and efficacy of Stereotactic Body Radiation 
      Therapy (SBRT) for unresectable liver metastasis in oligometastatic patients. 
      METHODS: Oligometastatic patients with up to three liver metastases of a maximum 
      diameter of 6 cm were treated with SBRT. Total dose was 75 Gy in three 
      consecutive fractions. Study endpoints were efficacy of this fractionation in 
      terms of local control (LC), overall survival (OS), toxicity, and prognostic 
      factors affecting OS and LC. RESULTS: Between February 2010 and December 2016, we 
      enrolled 202 patients, with a total of 268 unresectable liver metastases. Median 
      follow-up time from SBRT was 33 months (5-87 months). One-, 3‑, and 5‑year LC 
      rates were 92%, 84%, and 84%, respectively. In univariate analysis, the primary 
      histology and previous local ablative therapies were significant. Median OS was 
      21 months and the survival rates were 79%, 27%, and 15% at 1, 3, and 5 years 
      after SBRT, respectively. At univariate analysis, sex, primary disease histology, 
      intra-, and extra-hepatic progression were significant prognostic factors. This 
      analysis confirmed the absence of late toxicity >G3. CONCLUSION: This study 
      confirms the efficacy and safety of SBRT for unresectable liver metastases. 
      Selection of cases may improve survival and LC.
FAU - Clerici, Elena
AU  - Clerici E
AD  - Radiotherapy and Radiosurgery Department, Humanitas Cancer Center and Research 
      Hospital, Via Manzoni 56, 20089, Milan, Italy.
FAU - Comito, Tiziana
AU  - Comito T
AD  - Radiotherapy and Radiosurgery Department, Humanitas Cancer Center and Research 
      Hospital, Via Manzoni 56, 20089, Milan, Italy.
FAU - Franzese, Ciro
AU  - Franzese C
AD  - Radiotherapy and Radiosurgery Department, Humanitas Cancer Center and Research 
      Hospital, Via Manzoni 56, 20089, Milan, Italy. ciro.franzese@hunimed.eu.
AD  - Department of Biomedical Sciences, Humanitas University, Milan, Italy. 
      ciro.franzese@hunimed.eu.
FAU - Di Brina, Lucia
AU  - Di Brina L
AD  - Radiotherapy and Radiosurgery Department, Humanitas Cancer Center and Research 
      Hospital, Via Manzoni 56, 20089, Milan, Italy.
FAU - Tozzi, Angelo
AU  - Tozzi A
AD  - Radiotherapy and Radiosurgery Department, Humanitas Cancer Center and Research 
      Hospital, Via Manzoni 56, 20089, Milan, Italy.
FAU - Iftode, Cristina
AU  - Iftode C
AD  - Radiotherapy and Radiosurgery Department, Humanitas Cancer Center and Research 
      Hospital, Via Manzoni 56, 20089, Milan, Italy.
FAU - Navarria, Pierina
AU  - Navarria P
AD  - Radiotherapy and Radiosurgery Department, Humanitas Cancer Center and Research 
      Hospital, Via Manzoni 56, 20089, Milan, Italy.
FAU - Mancosu, Pietro
AU  - Mancosu P
AD  - Radiotherapy and Radiosurgery Department, Humanitas Cancer Center and Research 
      Hospital, Via Manzoni 56, 20089, Milan, Italy.
FAU - Reggiori, Giacomo
AU  - Reggiori G
AD  - Radiotherapy and Radiosurgery Department, Humanitas Cancer Center and Research 
      Hospital, Via Manzoni 56, 20089, Milan, Italy.
FAU - Tomatis, Stefano
AU  - Tomatis S
AD  - Radiotherapy and Radiosurgery Department, Humanitas Cancer Center and Research 
      Hospital, Via Manzoni 56, 20089, Milan, Italy.
FAU - Scorsetti, Marta
AU  - Scorsetti M
AD  - Radiotherapy and Radiosurgery Department, Humanitas Cancer Center and Research 
      Hospital, Via Manzoni 56, 20089, Milan, Italy.
AD  - Department of Biomedical Sciences, Humanitas University, Milan, Italy.
LA  - eng
PT  - Journal Article
TT  - Rolle von stereotaktischer Korperbestrahlungstherapie in der Behandlung von 
      Lebermetastasen: klinische Befunde und prognostische Faktoren.
DEP - 20191011
PL  - Germany
TA  - Strahlenther Onkol
JT  - Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et 
      al]
JID - 8603469
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Colorectal Neoplasms/mortality/*radiotherapy
MH  - Dose Fractionation, Radiation
MH  - Feasibility Studies
MH  - Female
MH  - Humans
MH  - Liver Neoplasms/mortality/*radiotherapy/*secondary
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Radiation Injuries/etiology
MH  - *Radiosurgery
MH  - Retrospective Studies
MH  - Survival Rate
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Ablation
OT  - Hepatic metastases
OT  - Oligometastases
OT  - Radiotherapy
OT  - Stereotactic ablative radiotherapy
EDAT- 2019/10/13 06:00
MHDA- 2020/10/22 06:00
CRDT- 2019/10/13 06:00
PHST- 2019/03/20 00:00 [received]
PHST- 2019/09/12 00:00 [accepted]
PHST- 2019/10/13 06:00 [pubmed]
PHST- 2020/10/22 06:00 [medline]
PHST- 2019/10/13 06:00 [entrez]
AID - 10.1007/s00066-019-01524-8 [pii]
AID - 10.1007/s00066-019-01524-8 [doi]
PST - ppublish
SO  - Strahlenther Onkol. 2020 Apr;196(4):325-333. doi: 10.1007/s00066-019-01524-8. 
      Epub 2019 Oct 11.